NRG
NMTC icon

Nemes Rush Group’s NeuroOne Medical Technologies NMTC Stock Holding History

Nemes Rush Group’s Portfolio NMTC Stock Details NMTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-72
Closed -$520 – 769
2024
Q3 		$520 Hold
72
– – ﹤0.01% 570
2024
Q2 		$346 Hold
72
– – ﹤0.01% 583
2024
Q1 		$520 Hold
72
– – ﹤0.01% 628
2023
Q4 		$685 Hold
72
– – ﹤0.01% 616
2023
Q3 		$386 Hold
72
– – ﹤0.01% 620
2023
Q2 		$520 Buy
+72
New +$583 ﹤0.01% 639

Other funds holding NMTC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
PGAM
Princeton Global Asset Management Princeton, New Jersey $698M AUM 31.09% 1-Year Est. Return

Nemes Rush Group's NMTC Position: Q4 2024 in Review

Nemes Rush Group sold out of NeuroOne Medical Technologies (NMTC) in Q4 2024, closing a stake of 72 shares — an estimated $520 sold.

Nemes Rush Group first reported a position in NMTC in Q2 2023 and held it in 6 quarters. The position peaked at $685 in Q4 2023. 20 funds tracked by Wall St. Rank hold NMTC as of Q4 2024.

  • Nemes Rush Group reported no remaining NeuroOne Medical Technologies position as of Q4 2024 after selling out during the quarter.
  • Nemes Rush Group sold 72 NeuroOne Medical Technologies shares in Q4 2024, an estimated $520.
  • Nemes Rush Group first reported a position in NeuroOne Medical Technologies in Q2 2023 and held it in 6 quarters.
  • Nemes Rush Group's NeuroOne Medical Technologies position peaked at $685 in Q4 2023.
  • 20 funds tracked by Wall St. Rank held NeuroOne Medical Technologies as of Q4 2024.

Based on Nemes Rush Group's 13F filing for Q4 2024, filed 12 Feb 2025.